Co-transplantation of human fetal thymic tissue and CD34 + fetal liver cells in NOD/SCID or NOD/SCID/γc -/-mice results in the development of multilineage human hematopoietic cells. In the present study, we show that these humanized mice had extremely low levels of human platelets. The presence of human megakaryocytes at a normal concentration in the bone marrow suggests that human megakaryocytic differentiation occurred efficiently in these mice. Rapid increase in human platelets in blood to levels comparable to those of human PBMCs following macrophage depletion indicates that mouse macrophages are responsible for the poor human platelet reconstitution in humanized mice. In support of this possibility, human platelets were rapidly rejected after infusion into untreated mice, but persisted in macrophage-depleted mice.
Introduction
Platelets are derived from megakaryocytes and play an essential role in normal hemostasis and thrombotic disorders. 1 Platelet transfusion is an effective means of preventing or treating bleeding, and an important supportive measure for patients undergoing transplantation or cytoreductive therapies. 2 In order to satisfy the excessive demand for platelets, considerable effort has been made to develop new approaches to platelet production. 3 Although immunodeficient mice have been widely used to study human lymphohematopoietic cell function in vivo, 4 there has been no report of achieving adequate human platelet reconstitution in these mice. [5] [6] [7] We have shown that co-transplantation of human fetal thymic tissue and CD34 + cells led to durable high levels of human hematopoietic reconstitution in NOD/SCID or NOD/SCID/γc -/-(NSG) mice. [8] [9] [10] In the present study, we show that human platelets were extremely low in these humanized mice, and failed human platelet reconstitution was caused by macrophage-mediated xenorejection, but not by defect in human megakaryocyte differentiation or platelet biogenesis.
Methods
Humanized mice were made by co-transplantation of human fetal thymic tissue (under the renal capsule) and CD34 + cells (i.v.), and human hematopoietic cell reconstitution was assessed by flow cytometry as previously described. 9; 11 The presence of human megakaryocytes in bone marrow of humanized mice was determined by flow cytometry and immunohistochemistry. 
Results and Discussion
Poor human platelet reconstitution in humanized mice. Blood collected from humanized NSG and NOD/SCID mice between 9 and 18 weeks after receiving human CD34 + cells or CD34 + cells plus human thymic tissue was analyzed for human platelet reconstitution. Consistent with our previous results, [8] [9] [10] humanized mice had high levels of human CD45 + cells in peripheral blood mononuclear cells (PBMCs; Figure 1A -B), including CD3 + T cells and CD19 + B cells (data not shown). The levels of human CD45 + cell chimerism were significantly greater in NSG mice than in NOD/SCID mice, with an average of 83% and 45%, respectively (p<0.001). However, the blood levels of human platelets in these mice were low, with an average of 1.6% and 1.2% for NSG and NOD/SCID mice, respectively ( Figure 1A-B) .
Presence of human megakaryocytes in humanized mice. Platelets are formed by megakaryocytes in the bone marrow and are subsequently released into the bloodstream.
Megakaryocytes account for a very small fraction (less than 1%) of bone marrow cells. 13 Figure 1C) . Furthermore, immunohistological staining of bone marrow tissue sections confirmed the presence of human CD61 + , morphologically mature megakaryocytes in humanized mice ( Figure 1D ). These data indicate that the mouse environment is capable of supporting efficient megakaryocyte differentiation, suggesting that the poor human platelet reconstitution may result from rapid clearance of human platelets in these mice. This is in accordance with a recent study 15 showing that immunodeficient knock-in mice expressing human thrombopoietin, a major growth factor in megakaryocyte development, 16 have no advantage in human platelet reconstitution after CD34 + cell transplantation.
Mouse macrophages mediate rapid rejection of human platelets in NOD/SCID mice.
Macrophages are professional phagocytic cells that are essential to host innate defense against infection. 17 We have recently shown that macrophages mediate robust rejection of human RBCs, but not nucleated hematopoietic cells in NOD/SCID and NSG mice. 11 To determine whether human platelets are also susceptible to rejection by mouse macrophages, we compared the survival of human platelets in NOD/SCID mice with or without macrophage depletion. It has been shown that injection of a large number of human RBCs (as "decoy cells") may delay rejection of subsequently infused human RBCs, likely due to transient saturation of the recipient mouse phagocytic system. 18 Such transient saturation of the recipient phagocytic system would also occur in mice receiving large numbers of human platelets if human platelets are susceptible
For personal use only. on September 24, 2017. by guest www.bloodjournal.org From 6 to phagocytosis by recipient macrophages. In order to determine an adequate number of human platelets to infuse, we performed a pilot experiment and found that human platelets were readily detectable in blood circulation in the first two days in NOD/SCID mice receiving 4x10 8 human platelets, but almost undetectable in those receiving 1.5x10 7 human platelets (data not shown).
Based on these data, we decided to infuse 1.5x10 7 human platelets in the experiment assessing the effect of macrophage depletion on human platelet survival. Compared to the control mice treated with PBS-liposomes, in which human platelets were rapidly cleared and became almost undetectable by 10 min after infusion, human platelet survival was significantly prolonged in mice that were depleted of macrophages by clodronate-liposomes (p<0.001; Figure 2A ). These results indicate that human platelets are highly susceptible to rejection by recipient macrophages in NOD/SCID mice.
CD47 is a ligand of SIRPα, an immune inhibitory receptor on macrophages. 19; 20 It has been demonstrated that CD47-SIRPα pathway prevents normal hematopoietic cells and platelets from phagocytosis by self macrophages, 19; 21; 22 and that the lack of efficient cross-reaction between donor CD47 and recipient SIRPα causes rejection of xenogeneic hematopoietic cells by macrophages. 23 ; 24 However, we found that xenogeneic human platelets were significantly more rapidly rejected than allogeneic CD47-deficient mouse platelets in NOD/SCID mice ( Figure S1 ), implicating that the vigorous rejection of human platelets by mouse phagocytic cells in humanized mice can be mediated by mechanisms other than a failure of CD47-SIRPα interaction.
This possibility is supported by previous studies showing that human CD47 is capable of interacting with NOD mouse SIRPα.
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For Figure 2C ). However, treatment with PBS-liposomes did not affect human platelet reconstitution in humanized mice ( Figure 2C ). The levels of human platelet chimerism in clodronate-treated mice were similar to the levels of human CD45 + cell chimerism during the course of treatment, indicating that macrophage depletion fully restored human platelet reconstitution ( Figure 2C ). These data indicate that the mouse hematopoietic microenvironment is capable of supporting human megakaryocyte maturation and platelet biogenesis, and that the poor human platelet reconstitution in humanized mice was mainly due to rejection by mouse macrophages. 
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